Nuclear texture analysis: A new prognostic tool in metastatic prostate cancer

Cytometry

Volumn 24, Issue 3, 1996, Pages 277-283

  Jørgensen, Trond ^a,c   Yogesan, Kanagasingam ^a   Tveter, Kjell J ^b   Skjørten, Fredrik ^b   Danielsen, Håvard E ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Kreftforeningen   (Norway)

Author keywords

Chromatin; Image analysis; Light microscopy; Prognosis; Prostate cancer; Texture

Indexed keywords

ARTICLE; CELL NUCLEUS; CHROMATIN; COMPUTER ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA;

AGED; AGED, 80 AND OVER; CELL NUCLEUS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 0029680199     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19960701)24:3<277::AID-CYTO11>3.0.CO;2-N     Document Type: Article

References (39)

1. Adolfsson J, Tribukait B: Modal DNA-values in prostate cancers patients with deferred therapy or endocrine therapy. Acta Oncol 30: 209-210, 1991.
2. Ahluwalia B, Jackson MA, Jones GW, Williams AO, Rao MS, Rajguru S: Blood hormone profiles in prostate cancer patients in high-risk, and low-risk populations. Cancer 48:2267-2273, 1981.
3. Chodac GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 265:618-621, 1991.
4. Christen R, Xiao J, Minimo C, Gibbons G, Fitzpatrick BT, Galera-Davidson H, Bartels PH, Bibbo M: Chromatin texture features in hematoxylin and eosin-stained prostate tissue. Anal Quant Cytol Histol 15:383-388, 1993.
5. Cockburn AG: Carcinoma of the prostate: Delayed endocrine therapy is the best. Semin Ural 1:280-287, 1983.
6. Danielsen HE, Farrants G, Reith A: Characterization of chromatin structure by image analysis - A method for the assessment of changes in chromatin organization. Scanning Microsc Suppl 3:297-302, 1989.
7. De Las Morenas A, Siroky MB, Merriam J, Stilmant M: Prostatic adenocarcinoma: Reproducibility and correlation with clinical stages of four grading systems. Hum Pathol 19:595-597, 1988.
8. Deligdisch L, Miranda C, Barba J, Gil J: Ovarian dysplasia: Nuclear texture analysis. Cancer 72:3253-3257, 1993.
9. Denis L, Mahler C: Prostatic cancer: An overview. Rev Oncol 3:665-677, 1990.
10. Dufer J, Liautaud-Roger F, Barbarin D, Coninx P: Nucleus image analysis as a possible prognostic tool in grading breast cancer. Biomed Pharmacother 47:131-135, 1993.
11. Edson Pontes J: Biological markers in prostate cancer. J Urol 130: 1037-1047, 1983.
12. Emrich LJ, Priore RL, Murphy GP, Brady MF: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45:5173-5179, 1985.
13. Feulgen R, Rossenbeck H: Mikroskopisch-chemischer nachweis einer nucleinsäure von typus der thymonucleinsäure und die darauf beru-hende elektive färbung von zellkerzen in mikroskopische präparaten. Z Physiol Chem 135:203-224, 1924.
14. Greenwood M: The natural duration of cancer. Reports on Public Health and Medical Subjects, 33: Her Majesty's Stationery Office, London, 1926, pp 1-26.
15. Harper ME, Pierrepoint CG, Griffiths K: Carcinoma of the prostate: Relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 20:477-482, 1984.
16. Hedley DW, Friedlander ML, Taylor IW: Application of DNA flow-cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 6:268-272, 1985.
17. Hedlund PO, Esposti P, Falkmer U, Jacobsson H: DNA as prognostic marker in advanced high-grade prostatic cancer. Acta Oncol 30: 215-217, 1991.
18. Høisæter PÅ: Alkaline phosphatase. A marker in prostatic cancer. Acta Oncol 30:171-172, 1991.
19. Irinopoulou T, Rigaut JP, Benson MC: Toward objective prognostic grading of prostatic carcinoma using image analysis. Anal Quant Cytol Histol 15:341-344, 1993.
20. Ishikawa S, Soloway MS, Van Der Zwaag R, Todd B: Prognostic factors in survival free of progression after androgcn deprivation therapy for treatment of prostate cancer. J Urol 141:1139-1142, 1989.
21. Jordan WP, Blackard CE, Byar DP: Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70: 1411-1413, 1977.
22. Jørgensen T, Tveter KJ, the members of SPCG-2 group, Jørgensen L: Total androgen suppression in metastatic prostatic cancer: Experience from the Scandinavian prostatic cancer group study No. 2. Eur Urol 24:466-470, 1993.
23. Jørgensen T, Müller C, Kaalhus O, Danielsen HE, Tveter KJ: Extent of disease based on initial bone scan. Important prognostic predictor for patients with metastatic prostatic cancer: Experience from the Scandinavian prostatic cancer group study No. 2. Eur Urol 28:40-46, 1995.
24. Jørgensen T, Yogesan K, Skjørten F, Berner A, Tveter KJ, Danielsen HE: Histopathological grading and DNA cytometry as prognostic markers in metastatic prostatic cancer. Br J Cancer 71:1055-1060, 1995.
25. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. John Wiley and Sons, New York, 1980, pp 10-20.
26. Kelly K, Scher HI: Prostate cancer: How can a common disease be so controversial. Curr Opin Oncol 6:318-331, 1994.
27. Komitowski DD, Hart MM, Janson CP: Chromatin organization and breast cancer prognosis. Cancer 72:1239-1246, 1993.
28. Mahler C, Denis L: Management of relapsing disease in prostate cancer. Cancer 70:329-334, 1992.
29. 2 prostate cancer. Prostate 24:306-312, 1994.
30. Mulder JWR, Johan GA, Offerhaus EP, Jeffrey J, Floyd SEK, Vogelstein B, Hamilton SR: The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am J Pathol 141:797-804, 1992.
31. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel MC, Pherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient Part 2. Analysis and examples. Br J Cancer 35:1-39, 1977.
32. Pienta KJ, Partin AW, Coffey DS: Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 49:2525-2532, 1989.
33. Schröder FH: Prostate cancer: To screen or not to screen? Br Med J 306:407-408, 1993.
34. Spirnak JP, Resnick MI: Carcinoma of the prostate: Early endocrine therapy is best. Semin Urol 1:269-279, 1983.
35. Van Velthoven R, Petein M, Zlotta A, Oosterlinc W, Van Der Meijden A, Zandona C, Roels H, Pasteels JL, Schulman C, Kiss R: Computer-assisted chromatin texture characterization of Feulgen-stained nuclei in a series of 331 transitional bladder cell carcinomas. J Pathol 173:235-242, 1994.
36. White RW deVere, Deitch AD, Tesluk H, Lamborn KR, Meyers FJ: Prognosis in disseminated prostate cancer as related to tumor ploidy and differentiation. World J Urol 8:47-50, 1990.
37. Yogesan K: Texture Analysis as a Prognostic and Diagnostic Tool in Tumor Pathology. Research Report No. 204. University of Oslo, Oslo, 1995.
38. Yogesan K, Albregtsen F, Reith A, Danielsen HE: Cooccurrence and run length based texture analysis of experimental liver carcinogenesis in mice. Proceedings of the 8th Scandinavian conference on image analysis, Vol 1, pp 227-234, Norway, 1993.
39. Yogesan K, Jørgensen T, Albregtsen F, Tveter KJ, Danielsen HE: Entropy-based texture analysis of chromatin structure in advanced prostate cancer. Cytometry 24:268-276, 1996.